AcouSort: Cell therapy collaboration with leading global life science company continues to expand

Regulatory

In January 2023, AcouSort reported that the company’s collaboration with a global life science company active within the cell therapy field had been extended with a second phase. The second phase of the collaboration has been brought to a successful close and the partnering company has now ordered an evaluation setup to internally assess the potential of AcouSort’s technology. The new activity will generate additional revenues of EUR 50 000 in 2023.

The continued collaboration aims to in more detail explore the robustness and adaptability of AcouSort’s AcouWash technology for the partner’s specific application and is an important step towards the development of OEM components to the partnering company’s future cell therapy products and instruments. This next step is yet another verification of the commercial potential of AcouSort’s focus on developing the technology towards OEM separation modules for cell therapy solutions in clinical settings.

“We are absolutely thrilled to see the positive development of this important collaboration as it perfectly fits our strategic commercial ambition to make the journey from partnering innovation to recurring sales of OEM components,” says AcouSort’s Commercial Director Agnes Michanek.

This information is information that AcouSort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on 5 July, at 8:50.

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.